ABCL Q2 2021 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$28M+146.2% YoY

Gross Profit

$24M86.9% margin

Operating Income

-$7M-25.4% margin

Net Income

-$2M-8.4% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

-86.4%

Cash Flow

Operating Cash Flow

$162M

Free Cash Flow

$124M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$184M

Stockholders' Equity

$968M

Cash & Equivalents

$793M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$28M	$11M	+146.2%
Gross Profit	$24M	$11M	+114.0%
Operating Income	-$7M	-$854,000	-723.5%
Net Income	-$2M	$7M	-134.7%

Revenue Segments

Royalty

$21M77%

Research Fees

$5M19%

Milestone Payments

$1M4%

License

$263,0001%